Of note, PD 173074, a well-known FGFR1 and VEGFR2 inhibitor failed to increase intracellular concentrations of Dox in both (parental and Tx-R) HCC 1806 cancer cells, as shown in Supplementary Figure S2. This evidence concerns the gene FGFR1 and cancer.